Pricing pressures, high raw material costs could cast damper on Q4 pharma earnings
NEW DELHI: Amid what has so far been a mixed scorecard for India Inc’s fourth quarter earnings, companies in the healthcare space are likely to report weak numbers in the last quarter due to a combination of factors, Nomura said. The headwinds for the sector include a slowdown in domestic formulation and seasonal weakness, persistent … Read more